[1] 汪建平, 王磊. 当前中国结直肠癌诊治所面临的问题和挑战[J]. 中华胃肠外科杂志, 2014, 17(5):521-524.
[2] 中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠肛门外科学组, 中国抗癌协会大肠癌专业委员会,等. 结直肠癌肝转移诊断和综合治疗指南(2016)[J]消化肿瘤杂志(电子版)的, 2017, 9(1):1-12.
[3] 蔡建强, 结直肠癌肝转移个体化综合治疗进展[J]. 肝癌电子杂志, 2014, 1(1):14-19.
[4] FALCONE A, RICCI S, BRUNETTI L et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLF0XIRI) compared with infusional fluorouracil, leucovorin, and irinotecan ( FOLFIRI) as first-line treatment for metastatic colorectal cancer:the Gruppo 0ncologico Nord 0vest[J].J Clin 0ncol, 2007, 25:1670-1676.
[5] LOUPAKIS F, CREMOLINI C, MASI G et al. Initial therapy with FOL FOXIRI and bevacizumab for metastatic colorectal cancer[J]. N EngI J Med, 2014x371(17):1609-1618.
[6] CREMOLINI C, MARMORINO F, LOUPAKIS F, et al.TRIBE-2:a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group[J]. BMC cancer, 2017, 17(1):408.
[7] GRUENBERGERT, BRIDGEWATERJ, CHAU I, et al.Bevacizumab plus mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer:the OLIVIA multinational randomized phaseⅡtrial[J]. AnnOncol, 2015, 26(4):702-708.
[8] SOUGLAKOS J, ANDROULAKIS N, SYRIGOS K, et al.FOLFOXIRI(folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and ininotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J], Br J Cancer, 2006, 94:798-805.
[9] VAMVAKAS L, ATHANASIADIS A, KARAMPEAZIS A, et al.Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI:Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Crit Rev Oncol Hematol, 2010, 76:61-70.
[10] CREMOLINI C, SCHIRRIPA M, ANTONIOTTI C, et al.First-line chemotherapy for mCRC-a review and evidence-based algorithm[J]. Nat Rev Clin Oncol, 2015, 12(10):607-619.
[11] CHEN E, LOREE J, JONKER DJ, et al.CCTG CO. 26:Updated analysis and impact of plasma-detected microsatellite stability(MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care(BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC)[J]. J Clin Oncol, 2019, abstr3512.
[12] FUKUOKA S, HARA H, TAKAHASHI N, et al.Regorafenid plus nivolumab in patients with advanced gastric or colorectal cancer:an open-label, dose-finding, and dose-expansion phase I b trial(REGONIVO, EPOC1603)[J]. J Clin Oncol, 2019, abstr2522. |
